The boundary between immune tolerance and immune attack is finely calibrated by a small population of regulatory T cells (Tregs), and disrupting that balance has enormous consequences — from runaway autoimmunity to tumors that evade destruction. A newly identified molecular switch in that calibration process could reshape how researchers think about engineering immunity for both cancer therapy and autoimmune disease.
Published in Science Advances, this study identifies the RNA-binding protein SRSF3 as a previously unrecognized master regulator of FOXP3, the transcription factor that defines Treg cell identity. Human FOXP3 exists in two isoforms, differentiated by whether exon 2 is included or skipped during pre-mRNA splicing. This study demonstrates that SRSF3 promotes exon 2 inclusion, thereby sustaining full-length FOXP3 protein expression and, consequently, Treg cell viability and suppressive capacity. Mice with Treg-specific deletion of Srsf3 developed lethal systemic inflammation — a phenotype consistent with catastrophic Treg failure. In human tumor microenvironments, Treg cells showed markedly elevated SRSF3 expression, and humanized mouse models carrying human FOXP3 exon 2 sequences exhibited meaningfully reduced tumor burden alongside increased CD8+ cytotoxic T-cell infiltration when Treg function was impaired.
This finding is significant for several reasons. FOXP3 splicing had been documented for years, but the upstream regulatory machinery had remained opaque. Placing SRSF3 at that control point connects RNA splicing biology to adaptive immune identity in a mechanistically concrete way. From a therapeutic standpoint, SRSF3 represents a potentially actionable target: inhibiting it in tumor-infiltrating Tregs could theoretically reinvigorate antitumor CD8+ responses without systemic immunosuppression. However, critical caveats apply. Much of the mechanistic data derives from mouse genetic models, and translating splicing-based interventions to humans is technically demanding. The dual role of SRSF3 — relevant to both autoimmune restraint and tumor immune evasion — also introduces serious off-target risks. This is incremental-to-significant mechanistic work that warrants attention from immunotherapy researchers, though clinical translation remains distant.